Brofaromine
Overview of the antidepressant drug Brofaromine
| Brofaromine | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA) that was developed as an antidepressant and anxiolytic agent. It belongs to the class of monoamine oxidase inhibitors (MAOIs), which are used to treat depression by increasing the levels of neurotransmitters in the brain.
Mechanism of Action
Brofaromine works by selectively inhibiting the enzyme monoamine oxidase A (MAO-A). This enzyme is responsible for breaking down monoamines such as serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, brofaromine increases the availability of these neurotransmitters, which can help alleviate symptoms of depression and anxiety.
Pharmacokinetics
Brofaromine is absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism. It has a relatively short half-life, which allows for reversible inhibition of MAO-A, reducing the risk of hypertensive crisis associated with traditional MAOIs.
Clinical Use
Brofaromine was investigated for the treatment of major depressive disorder and anxiety disorders. However, it was never marketed due to the development of newer antidepressants with more favorable side effect profiles.
Side Effects
Common side effects of brofaromine include nausea, headache, and insomnia. Unlike traditional MAOIs, brofaromine has a lower risk of causing tyramine-induced hypertensive crisis, allowing for a less restrictive diet.
Development and History
Brofaromine was developed in the 1980s and underwent clinical trials to assess its efficacy and safety. Despite promising results, it was not brought to market, partly due to the emergence of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants that offered similar benefits with fewer dietary restrictions and side effects.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian